Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (171-180 of 499) with videos related to

Pageof 50
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2020
[<sup>18</sup>F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [<sup>68</sup>Ga]Ga-DOTATATE in neuroendocrine tumour patientsElin Pauwels, Frederik Cleeren, Térence Tshibangu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 2, 2019
Al<sup>18</sup>F-NOTA-octreotide: first comparison with <sup>68</sup>Ga-DOTATATE in a neuroendocrine tumour patientElin Pauwels, Frederik Cleeren, Térence Tshibangu, et al.
The New England Journal of Medicine|July 23, 2004
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerDavid Cunningham, Yves Humblet, Salvatore Siena, et al.
Investigational New Drugs|September 13, 2014
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulationsTakayuki Yoshino, Yoshito Komatsu, Yasuhide Yamada, et al.
Pancreas|December 6, 2014
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trialCatherine Lombard-Bohas, James C Yao, Timothy Hobday, et al.
Endocrine-Related Cancer|September 17, 2015
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysisJonathan R Strosberg, James C Yao, Emilio Bajetta, et al.
Journal of Geriatric Oncology|November 15, 2017
Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS)Lore Decoster, Cindy Kenis, Benedicte Naessens, et al.
Frontiers in Oncology|January 31, 2025
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancerJulien Taieb, Marwan Fakih, Gabor Liposits, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 24, 2022
[<sup>68</sup>Ga]Ga-DOTATATE-avid tumor volume, uptake and inflammation-based index correlate with survival in neuroendocrine tumor patients treated with [<sup>177</sup>Lu]Lu-DOTATATE PRRTElin Pauwels, Jeroen Dekervel, Chris Verslype, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2010
A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinomaHannah van Malenstein, Olivier Gevaert, Louis Libbrecht, et al.
Pageof 50

Showing results (171-180 of 499) with videos related to

Sort By:
Pageof 50
European Journal of Nuclear Medicine and Molecular Imaging|July 4, 2020
[<sup>18</sup>F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [<sup>68</sup>Ga]Ga-DOTATATE in neuroendocrine tumour patientsElin Pauwels, Frederik Cleeren, Térence Tshibangu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 2, 2019
Al<sup>18</sup>F-NOTA-octreotide: first comparison with <sup>68</sup>Ga-DOTATATE in a neuroendocrine tumour patientElin Pauwels, Frederik Cleeren, Térence Tshibangu, et al.
The New England Journal of Medicine|July 23, 2004
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancerDavid Cunningham, Yves Humblet, Salvatore Siena, et al.
Investigational New Drugs|September 13, 2014
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulationsTakayuki Yoshino, Yoshito Komatsu, Yasuhide Yamada, et al.
Pancreas|December 6, 2014
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trialCatherine Lombard-Bohas, James C Yao, Timothy Hobday, et al.
Endocrine-Related Cancer|September 17, 2015
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysisJonathan R Strosberg, James C Yao, Emilio Bajetta, et al.
Journal of Geriatric Oncology|November 15, 2017
Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS)Lore Decoster, Cindy Kenis, Benedicte Naessens, et al.
Frontiers in Oncology|January 31, 2025
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancerJulien Taieb, Marwan Fakih, Gabor Liposits, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 24, 2022
[<sup>68</sup>Ga]Ga-DOTATATE-avid tumor volume, uptake and inflammation-based index correlate with survival in neuroendocrine tumor patients treated with [<sup>177</sup>Lu]Lu-DOTATATE PRRTElin Pauwels, Jeroen Dekervel, Chris Verslype, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 2010
A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinomaHannah van Malenstein, Olivier Gevaert, Louis Libbrecht, et al.
Pageof 50